Real-time enrollment status for this rare unresectable or metastatic braf v600e mutation-positive solid tumors clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 11:02 AM UTC
| NCT Number | NCT05868629 |
| Recruiting Status | Recruiting |
| Condition | Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors |
| Phase | Clinical Trial |
| Target Enrollment | 40 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | April 1, 2026 (Apr 1, 2026) |
As of July 13, 2026: Clinical trial NCT05868629 is currently recruiting participants. This clinical trial study for rare unresectable or metastatic braf v600e mutation-positive solid tumors is actively seeking new participants at 8 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05868629 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05868629 was last updated Apr 1, 2026 (April 1, 2026). HelloStudys verifies this status automatically.